Skip to main content

Monovisc® Injection Therapy

High-dose, single-injection hyaluronic acid for symptomatic osteoarthritis across multiple joints

High-dose, single-injection hyaluronic acid for symptomatic osteoarthritis across multiple joints

Order products
Discuss with Eos Active

Monovisc® – developed to enhance movement and joint longevity

Monovisc is a high-dose hyaluronic acid (HA) injection designed to support joint function and reduce pain in osteoarthritis. It is used as a single intra-articular injection and is designed for clinics that want a straightforward, evidence-based viscosupplement option with a strong clinical heritage.

Licensed extensively proven for use in the Ankle, Knee, Hip and Shoulder joints, Monovisc naturally occurring range of molecular weights ensures optimum lubrication, cushioning and endogenous HA stimulation. 

Over 3 million Monovisc single injections have been admistered world-wide.

The Technology

High-dose, optimally crosslinked, natural molecular weight bandwidth for longevity

Each pre-filled syringe contains 4 mL, delivering 88mg of ultra-pure hyaluronan.

Monovisc is:

  • Non-animal derived (fermentation sourced)
  • Lightly / partially cross-linked for molecular stability and intra-articular longevity
  • Designed to be biocompatible and resorbable
  • Proven to produce an incredibly low risk of adverse events and flares

While some other HA’ are chemically bonded to achieve a molecular weight range, Monovisc was first developed with this in mind, and the HA covers molecular weights that support joint lubrication, joint cushioning, and very importantly, synvioyte ingergration that supports endogenous HA production. 

Clinical Rationale

The constitution of the hyaluron matters; Monovisc had it right from the start

Osteoarthritis is not only about cartilage wear. Many patients experience symptoms driven by a combination of:

  • Reduced synovial lubrication and shock absorption
  • Altered joint mechanics and load transfer
  • A joint environment that becomes less supportive of normal movement

Monovisc is designed to support the joint environment by:

  • Improving the viscoelastic properties of synovial fluid
  • Supporting lubrication and glide
  • Helping reduce pain and stiffness so patients can move, strengthen, and re-load more effectively
  • Give long-term support by optimising the positive effect on synoviosytes

Monovisc becomes the “base layer” of injection therapy.

Clinical data headlines

Monovisc has been evaluated in high-quality clinical studies in symptomatic knee osteoarthritis, including multicentre, double-blind, randomised, placebo-controlled trials.

Key points to highlight:

  • Demonstrated clinically meaningful pain reduction, with improvement seen as early as 2 weeks in trial populations
  • A statistically significantly higher rate of patient success versus saline at key timepoints (based on standardised WOMAC pain success criteria)
  • Sustained benefit through follow-up periods up to 26 weeks
  • Favourable safety and tolerability profile, level study showing 2% minor adverse events (skin irritation)

This section is designed for scan-reading. Full papers, protocols, and detailed endpoints sit within the Eos Active clinical library.

Where Monovisc® Fits in Clinical Practice

A versatile, simple and proven option for modern OA management

Monovisc is typically considered for patients who:

  • Have symptomatic osteoarthritis where inflammation is not the dominant feature
  • Want a non-operative option focused on longer-term joint support
  • Have not achieved sufficient improvement with conservative care alone
  • Need symptom improvement to better engage with rehab, strength work, and activity modification

In real-world clinic pathways, Monovisc is often used:

  • As a first-line HA option where a steroid is not indicated
  • As a repeatable treatment in patients who respond well and want ongoing support
  • Alongside physiotherapy, weight management, bracing, and longer-term joint health strategies
  • Clinics where one solution fits mulitple joints (Ankle, Knee, Hip, Shoulder)

Supported by Eos Active

Monovisc is not positioned as a standalone product. At Eos Active, we support its use as part of a considered, ethical, and sustainable injection service, one that works for clinicians, clinics, and patients.

Our support is designed to remove friction around adoption, communication, and delivery, so the focus stays on good clinical decision‑making rather than product justification.

Clinical confidence and education

  • Ongoing education around injection therapy, osteoarthritis management, and treatment selection
  • Access to a growing clinical library with key papers, summaries, and practical guidance
  • Support in understanding where Monovisc fits relative to pure steroid, Cingal, PRP, and other non‑operative options

Patient communication and consent support

  • Clear, balanced patient‑facing materials explaining what Monovisc is, and what it is not
  • Language that helps patients understand the rationale for a HA treatment without overselling the product option
  • Resources that support informed consent and realistic expectation setting

Practice integration

  • Guidance on how Monovisc can sit within existing clinic pathways
  • Support aligning injection therapy with physiotherapy, rehabilitation, and longer‑term joint care
  • Help structuring services so treatments feel joined‑up rather than transactional

A partnership approach

  • Direct access to Eos Active for discussion, questions, and support
  • A long‑term relationship built around service development, not short‑term volume
  • A shared focus on evidence‑led care and maintaining professional credibility

A Summary of Monovisc®

Monovisc is a single-injection, high-dose hyaluronic acid treatment for osteoarthritis, designed for patients who need sustained joint support without a steroid component. It fits naturally within modern non-operative pathways, supporting movement, rehabilitation, and longer-term joint health.

Eos Active, of course have many other options and complementary products which you can learn more about.

Eos Active Portfolio

Book a call or get in touch

Discuss with our Managing Director, Jim, to learn more about Orthovisc, and so we know where and how to work best with you.
Eos Active Contact